Table 1 Baseline demographics and clinical characteristics of study participants

From: Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial

Category

PG-102

Placebo (n = 6)

Total (n = 24)

15 mg (n = 6)

30 mg (n = 6)

30/60 mg (n = 6)

Age (years)

30.3 ± 6.1

31.3 ± 7.8

28.5 ± 5.7

33.5 ± 7.8

30.9 ( ± 6.7)

Female, n (%)

1 (16.7%)

1 (16.7%)

0 (0%)

0 (0%)

2 (8.3%)

Male n (%)

5 (83.3%)

5 (83.3%)

6 (100%)

6 (100%)

22 (91.7%)

Body weight (kg)

77.6 ± 3.5

80.0 ± 9.7

81.9 ± 5.2

82.8 ± 8.6

80.6 ( ± 7.0)

BMI (kg per m²)

26.7 ± 1.2

27.0 ± 1.2

26.5 ± 0.3

27.7 ± 1.5

27.0 ( ± 1.2)

  1. Summary of demographic and baseline characteristics of participants (n = 24) across treatment groups. Data are presented as mean ± SD for continuous variables and n (%) for categorical variables. Sex was determined based on self-report at screening. Given to the very small number of female participants (n = 2), no sex-based subgroup analysis was performed.
  2. n number of subjects, BMI body mass index.
Back to article page